shelf(0)

No. 012 · GH & Growth · Growth Hormone

Tesamorelin

EgriftaEgrifta SVEgrifta WRTH9507

S Tier S · Approved how tiers work →
  • FDA approved 2010
  • WADA ✗ S2
Compare Cite
Fingerprint no sequence
Tesamorelin (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Quick answers

What is Tesamorelin?
An FDA-approved GHRH analog specifically indicated for HIV-associated lipodystrophy.
How strong is the evidence for Tesamorelin?
Tier S (approved) on the peptidemeta evidence scale. FDA-approved (Egrifta) to reduce excess abdominal fat in HIV-associated lipodystrophy, based on phase 3 RCTs.
Is Tesamorelin FDA-approved?
Yes. The FDA approved Tesamorelin (Egrifta) in 2010. Reduction of excess abdominal fat in adults with HIV and lipodystrophy.
Is Tesamorelin banned in sport?
Yes. Tesamorelin is prohibited in sport by the World Anti-Doping Agency under S2 (peptide hormones, growth factors, related substances and mimetics).
How does Tesamorelin work?
Tesamorelin is a synthetic GHRH analog with a trans-3-hexenoic acid modification that increases enzymatic stability. It binds the GHRH receptor on pituitary somatotrophs, stimulating physiological GH release.
What is known about the safety of Tesamorelin?
FDA-approved (Egrifta) with Phase III safety data. Common side effects: injection site reactions, arthralgia, peripheral edema, myalgia.

Last reviewed · editorial policy · markdown

02

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER S — Approved by the FDA or EMA for at least one indication.

FDA-approved (Egrifta) to reduce excess abdominal fat in HIV-associated lipodystrophy, based on phase 3 RCTs.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

03

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Approved (2010) Egrifta Reduction of excess abdominal fat in adults with HIV and lipodystrophy.
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
04

Overview

An FDA-approved GHRH analog specifically indicated for HIV-associated lipodystrophy. It reduces visceral fat while preserving subcutaneous fat and lean mass.

Research status FDA-approved (Egrifta) for HIV-associated lipodystrophy; robust Phase III clinical trial data

05

Mechanism

Tesamorelin is a synthetic GHRH analog with a trans-3-hexenoic acid modification that increases enzymatic stability. It binds the GHRH receptor on pituitary somatotrophs, stimulating physiological GH release. The resulting GH and IGF-1 elevation promotes visceral adipose lipolysis while preserving subcutaneous fat distribution.

06

Effects reported in research

Reported outcomes, not promises. Some come from controlled human trials; others may be from smaller or preclinical studies — check the studies below.

  • Significant visceral fat reduction
  • Increased IGF-1 to physiological levels
  • Improved lipid profiles
  • Preserved lean body mass
07

Safety & unknowns

FDA-approved (Egrifta) with Phase III safety data. Common side effects: injection site reactions, arthralgia, peripheral edema, myalgia. Contraindicated in active malignancy and pregnancy. Monitor IGF-1 levels during treatment.

Unknowns. Trial safety data apply to the populations, formulations and conditions studied.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

08

Studies [0]

No studies cited for this entry yet.

10

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

11

Cite this entry

$ cite --format=apa

peptidemeta. (2026). Tesamorelin. In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/tesamorelin/

$ cite --format=bibtex 
@misc{peptidemeta-tesamorelin,
  title = {Tesamorelin},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/tesamorelin/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open